Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes.
Sommeijer
D W
DW
Laboratory for Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. dwsommeijer@hotmail.com
Joop
K
K
Leyte
A
A
Reitsma
P H
PH
ten Cate
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000648:ultrastructure*; D002784:Cholesterol / Q000097:blood; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D039661:Integrin beta3 / Q000032:analysis / Q000187:drug effects*; D046911:Macromolecular Substances / Q000097:blood / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation; D017035:Pravastatin / Q000494:pharmacology* / Q000627:therapeutic use
D039661:Integrin beta3; D046911:Macromolecular Substances; D002784:Cholesterol; D017035:Pravastatin